Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Multiple Myeloma Clinical Trials

Protocol Number Title
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders From Digital Upgrade to Digital Revolution: A New Era in Survivor Research
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
MT2013-06C : Treatment of graft Failure after HSCT
MT2013-09C : Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
MT2014-33R: Continued Long-Term Follow-up and Lenalidomide Maintenance Therapy for Patients Who have Enrolled on CTN 0702 (CTN 07LT)
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
Family-based studies of susceptibility to early onset disease
MT2015-11 : Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (CTN1302)
MT2016-04 :Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination of Dendritic Cell/Myeloma Fusions (CTN 1401)
MT2015-46 : A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
MT2015-17C :Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
MT2015-32C : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
MT2016-13 :A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (CTN 1501)
MT2016-33 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Corticosteroids in Patients with New Onset Chronic Graft Versus Host Disease (cGVHD)
HM2016-16 : Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies
MT2016-10: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease
MT2016-31 A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
MT2016-36 A Phase I, Multicenter, Open-label, safety of Human Cord Blood Derived, Culture-Expanded, Natural Killer Cell (PNK-007) Infusion with subcutaneous Recombinant Human IL-2 (RHIL-2) following autologous stem cell transplant for Multiple Myeloma
MT2016-35 Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
HM2017-21 The Role of Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction Chemotherapy
Collaborative Perinatal Project Minnesota Cohort Follow-up Study (CPP-MN 2.0)

23 trials displayed